Skip to main content

Advertisement

Advertisement

ADVERTISEMENT

September/October 2015

Department

Meet the Board
10/29/2015
Led by Editor-in-Chief Winston Wong, PharmD, the Editorial Advisory Board will advise Journal of Clinical Pathways Editors on the editorial direction of the journal to ensure that its mission of presenting the timeliest and highest quality...
Led by Editor-in-Chief Winston Wong, PharmD, the Editorial Advisory Board will advise Journal of Clinical Pathways Editors on the editorial direction of the journal to ensure that its mission of presenting the timeliest and highest quality...
Led by Editor-in-Chief Winston...
10/29/2015
Journal of Clinical Pathways
Research in Review
10/29/2015
J Clin Pathways. 2016;2(1):9-12. Impact of Alternative Payment Models on Personalized Medicine Personalized medicine is changing the landscape in the battle against cancer. In the midst of this progress, is the trend toward value-based...
J Clin Pathways. 2016;2(1):9-12. Impact of Alternative Payment Models on Personalized Medicine Personalized medicine is changing the landscape in the battle against cancer. In the midst of this progress, is the trend toward value-based...
J Clin Pathways....
10/29/2015
Journal of Clinical Pathways
Conferences
10/27/2015
JCP Editors
The National Association of Specialty Pharmacy is a trade association dedicated to education, national policy advocacy, and engagement of all stakeholders in the specialty pharmacy industry.
The National Association of Specialty Pharmacy is a trade association dedicated to education, national policy advocacy, and engagement of all stakeholders in the specialty pharmacy industry.
The National Association of...
10/27/2015
Journal of Clinical Pathways

Feature

Perspectives
10/28/2015
Alex Bastian, MBA
Deeksha Dua, MBBS, MPH
Sahand Mirzahossein, MBA
In this article, the authors review the types of RSAs that have been implemented to date, with a specific focus on two European countries (the United Kingdom and Italy) and on the United States.
In this article, the authors review the types of RSAs that have been implemented to date, with a specific focus on two European countries (the United Kingdom and Italy) and on the United States.
In this article, the authors...
10/28/2015
Journal of Clinical Pathways
Research Reports
10/27/2015
Merena Nanavaty, MS, BPharm
Satyin Kaura MSC, MBA
Mkaya Mwamburi, MD, PhD, MA [Econ]
Anagha Gogate, BA
John Proach, MBA
Abner Nyandege, PhD
Zeba M. Khan, RPh, PhD
Abstract: The incremental cost-effectiveness ratio (ICER) is used to determine the cost-effectiveness of new health care interventions. A literature review was conducted to determine the ICER thresholds used by...
Abstract: The incremental cost-effectiveness ratio (ICER) is used to determine the cost-effectiveness of new health care interventions. A literature review was conducted to determine the ICER thresholds used by...
...
10/27/2015
Journal of Clinical Pathways
Feature
10/27/2015
Winston Wong, PharmD, Editor-in-Chief
Abstract: A substantial portion of total medication costs is represented by the cost of specialty drugs, which only continues to rise. Oncology, in particular, is one of the three most costly specialty therapeutic...
Abstract: A substantial portion of total medication costs is represented by the cost of specialty drugs, which only continues to rise. Oncology, in particular, is one of the three most costly specialty therapeutic...
...
10/27/2015
Journal of Clinical Pathways

Column

Viewpoint
10/27/2015
Gary Owens, MD
The August 2015 edition of the Mayo Clinic Proceedings featured an article entitled, “In Support of a Patient-Driven Initiative and Petition to Lower the High Price of Cancer Drugs”.1 In that article, the authors...
The August 2015 edition of the Mayo Clinic Proceedings featured an article entitled, “In Support of a Patient-Driven Initiative and Petition to Lower the High Price of Cancer Drugs”.1 In that article, the authors...
The...
10/27/2015
Journal of Clinical Pathways
Counterpoint
10/27/2015
David R. Henderson, PhD
Charles L. Hooper, MS
Are there ways to make drugs more affordable without reducing the incentive to innovate? Dr. Owens makes two principal claims with which we agree. Any dialogue about the rising cost of cancer drugs must, as the...
Are there ways to make drugs more affordable without reducing the incentive to innovate? Dr. Owens makes two principal claims with which we agree. Any dialogue about the rising cost of cancer drugs must, as the...
Are...
10/27/2015
Journal of Clinical Pathways

Insights

Interview
10/27/2015
JCP Editors
Erin Hagan, MBA, PhD, discusses Evidence for Action, a national program of the Robert Wood Johnson Foundation designed to support high-impact action-oriented research to assess population health and health care outcomes and set priorities for...
Erin Hagan, MBA, PhD, discusses Evidence for Action, a national program of the Robert Wood Johnson Foundation designed to support high-impact action-oriented research to assess population health and health care outcomes and set priorities for...
Erin Hagan, MBA, PhD, discusses...
10/27/2015
Journal of Clinical Pathways
Interview
10/27/2015
Richard Schilsky, MD, FACP, FASCO, spoke with Journal of Clinical Pathways about some of the forces that led to the development of the ASCO Value Framework and considerations that influenced its design.
Richard Schilsky, MD, FACP, FASCO, spoke with Journal of Clinical Pathways about some of the forces that led to the development of the ASCO Value Framework and considerations that influenced its design.
Richard Schilsky, MD, FACP,...
10/27/2015
Journal of Clinical Pathways

Advertisement

Advertisement

Advertisement